|
Statement of Financial Position (USD $)
|
Sep. 30, 2014
|
Mar. 31, 2014
|
| Assets, Current |
|
|
| Cash and Cash Equivalents, at Carrying Value |
$ 907,302 |
$ 1,873,141 |
| Prepayments and Other Assets |
50,562 |
20,390 |
| Prepayment to Related Party for clinical trials |
510,035 |
|
| Assets, Current |
1,467,899 |
1,893,531 |
| Assets, Noncurrent |
|
|
| Finite-Lived Intangible Assets, Net |
91,524 |
70,781 |
| Restricted Cash, Noncurrent |
|
85,462 |
| Tangible Fixed Assets |
6,064 |
|
| Assets, Noncurrent |
97,588 |
156,243 |
| Assets |
1,565,487 |
2,049,774 |
| Liabilities, Current |
|
|
| Accounts Payable, Current |
138,656 |
1,830 |
| Other Liabilities, Current |
8,612 |
6,844 |
| Liabilities, Current |
147,268 |
8,674 |
| Liabilities, Noncurrent |
|
|
| Deferred Revenue and Credits, Noncurrent |
1,664,600 |
1,667,200 |
| Liabilities, Noncurrent |
1,664,600 |
1,667,200 |
| Liabilities |
1,811,868 |
1,675,874 |
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|
|
| Common Stock, Value, Issued |
200,000 |
200,000 |
| Additional Paid in Capital, Common Stock |
2,924,672 |
2,924,672 |
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
(4,028) |
(8,882) |
| Retained Earnings (Accumulated Deficit) |
(3,367,025) |
(2,741,890) |
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
(246,381) |
373,900 |
| Liabilities and Equity |
$ 1,565,487 |
$ 2,049,774 |